Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bilayer vesicles, most commonly known as liposomes, are spherical structures composed of one or more lipid bilayers surrounding an aqueous core. They are not therapeutic targets in the traditional sense, such as receptors or enzymes; rather, they serve as sophisticated drug delivery platforms designed to transport therapeutic agents to specific tissues or cells. By mimicking biological membranes, these vesicles can encapsulate both hydrophilic and hydrophobic drugs, protecting them from metabolic degradation and reducing off-target toxicities. In clinical practice, bilayer vesicles are utilized to improve the therapeutic index of potent drugs like doxorubicin and amphotericin B. Their properties, including size, charge, and surface modifications (e.g., PEGylation), are engineered to optimize circulation time and cellular uptake.
Bilayer vesicles act as delivery vehicles that encapsulate therapeutic agents, protecting them from degradation and enhancing their pharmacokinetic profile by facilitating targeted delivery and reducing systemic toxicity.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bilayer vesicles (BV).